Company: PRTA
Filing Date: 2025-03-28
Form Type: DEF 14A
Source: 0001559053-25-000017
Chunk: 43

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-03-28
Form: DEF 14A
Chunk 43
---
8 LTIP and the 2012 LTIP:

• 10,424,163 of our ordinary shares were subject to outstanding option awards, with a weighted average exercise price of $28.32 and a weighted average remaining term of 6.00 years;

• 6,000 ordinary shares were subject to unvested restricted share unit awards;

• No ordinary shares were subject to any other types of outstanding awards; and

• 3,857,181 ordinary shares remained available for future grant under the 2018 LTIP.

On February 25, 2020, our Board approved our 2020 Employment Inducement Incentive Plan, and subsequently adopted a series of amendments to increase the ordinary shares available for issuance under such plan (as amended, the “2020 EIIP”). Since adoption through the Record Date, we have used the 2020 EIIP to induce our Chief Business Officer (now our Chief Operating Officer) and 24 other employees at the director level and above to join the Company. As of March 3, 2025, under the 2020 EIIP:

• 703,246 of our ordinary shares were subject to new-hire option awards, with a weighted average exercise price of $33.06, and a weighted average remaining term of 6.17 years;

• No ordinary shares were subject to any other types of outstanding awards; and

• 341,584 ordinary shares remained available for future grant under the 2020 EIIP, but the Board and the Compensation Committee reserve the right to further amend the 2020 EIIP from time-to-time to increase the number of ordinary shares available for issuance and to make additional awards to key new-hires.

Thus, as of March 3, 2025, under the 2018 LTIP, the 2012 LTIP, and the 2020 EIIP:

• 11,127,409 of our ordinary shares were subject to outstanding option awards, with a weighted average exercise price of $28.62 and a weighted average remaining term of 6.01 years;

• 6,000 ordinary shares were subject to unvested restricted share unit awards;

• No ordinary shares were subject to any other types of outstanding awards; and

• 4,198,765 ordinary shares remained available for future grant under the 2018 LTIP and the 2020 EIIP.

The closing price of our ordinary shares on March 3, 2025, was $14.33 per share